Clinical Trial Update: Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating sustained interferon alfa-2b therapy delivered via the InfraDure Biopump for relapsing Hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Medgenics Medical Israel Ltd. | Conditions: Hepatitis C | Phase 1, Phase 2 | Status: WITHDRAWN